Phase I Trial of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder for Adults with Relapsed/Refractory B-ALL

Jordan Gauthier(Seattle Cancer Care Alliance), Cameron J. Turtle(The University of Sydney), David G. Maloney(Fred Hutch Cancer Center), Delaney R. Kirchmeier(Fred Hutch Cancer Center), Nicolas Gazeau(Centre Hospitalier Universitaire de Lille), Henna A Di(Fred Hutch Cancer Center), Alexandre V. Hirayama(University of Washington), Salvatore Fiorenza, Mazyar Shadman(University of Washington), Ryan D. Cassaday(University of Washington), Stanley R. Riddell(Fred Hutch Cancer Center), Barbara S. Pender, Erik L. Kimble(University of Washington)
Transplantation and Cellular Therapy
February 1, 2023
10.1016/s2666-6367(23)00193-8
Cited by 1

Related Papers

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor
|New England Journal of Medicine|1995|1.8k
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
|Blood|2001|1.4k
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
|Blood|2017|1.1k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795